Quick Summary
Alveofact 50mg Injection
Last updated on 31 Mar 2026 | 09:31 AM (IST)
₹2851
MRP: ₹3520
(You Save ₹669)
1 VIAL(s)
Alveofact 50mg Injection
Salt Composition
PHOSPHOLIPID FRACTION FROM BOVINE LUNG (SURFACTANT)
Marketer
BHARAT SERUMS & VACCINES LTD
19% OFF
₹2851
MRP: ₹3,520.00
Inclusive of all taxes
19% Off
Salt Composition
PHOSPHOLIPID FRACTION FROM BOVINE LUNG (SURFACTANT)
Marketer
BHARAT SERUMS & VACCINES LTD
Product Discontinued
Dispatch: Today
Order In: 0h 0m 0s
0h 0m 0s
Order before timer ends to ensure your medicine is dispatched at...
Introduction to Alveofact 50mg Injection
Alveofact 50mg Injection contains an active component called Phospholipid fraction from bovine lung. It is used as medication primarily in the treatment of respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs don't produce enough surfactant, a substance essential for maintaining the lungs' elasticity and preventing alveoli collapse. In severe cases of pneumonia, especially in premature infants or newborns, where lung function is compromised, this medication might be used to support breathing. In some cases, this medication might assist with lung function when babies pass stool (meconium) while still in the womb and inhale it into their lungs before or during delivery, causing breathing problems.
Individuals with known severe allergies to components of the Alveofact 50mg Injection or any of its components should not receive it. In some cases, active or severe infections may be a contraindication to this medication due to the potential risk of worsening the infection or complicating the treatment. It might not be recommended for infants above a certain gestational age or weight threshold, as their lung maturity might not benefit from this intervention. If the patient has a severe bleeding disorder or an increased risk of bleeding, administering it may pose a risk of bleeding into the lungs or exacerbate bleeding issues, so should consult a healthcare provider before taking it. Alveofact 50mg Injection is primarily used in neonatal care and is not typically administered to older adults.
Uses of Alveofact 50mg Injection
- Neonatal respiratory distress syndrome (RDS)
- Meconium aspiration syndrome
- Pneumonia
- Acute respiratory distress syndrome (ARDS)
- Lung surfactant deficiency
Therapeutic Effects of Alveofact 50mg Injection
Alveofact 50mg Injection reduces surface tension at the air-liquid interface in the lungs' alveoli, preventing collapse during exhalation and ensuring these tiny air sacs stay open for gas exchange. Composed of lipids and proteins, it enhances lung compliance, making breathing easier. In conditions like respiratory distress syndrome (RDS) or surfactant deficiencies, surfactant replacement therapy supplements or replaces insufficient surfactant, improving lung function and preventing breathing complications.
Interaction of Alveofact 50mg Injection with other drugs
Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with the Alveofact 50mg Injection, reducing effectiveness by causing undesirable side effects.
More Information about Alveofact 50mg Injection
- Stored at controlled room temperature, between 2°C to 8°C
- Keep away from moisture, heat, and light.
- It should not be frozen.
- Keep away from children and pets.
How to consume Alveofact 50mg Injection
Alveofact 50mg Injection should be used only when there is enough facility for ventilation and monitoring. This medicine should be administered via the intra-tracheal route. Your baby’s physician and nurse should constantly monitor to ensure that the right amount of oxygen is given. Dosing shall be stopped by the physician in case of a slow heartbeat or reduced oxygen in circulation and resumed only after the condition is stable.
Safety Advice for Alveofact 50mg Injection
Breast Feeding
Breastfeeding individuals should consult healthcare providers before handling or administering Alveofact 50mg Injection due to potential risks associated with exposure to the medication or its residues.
Alcohol
There's no direct contraindication regarding alcohol consumption and Alveofact 50mg Injection. Consult your healthcare provider for better advice.
Liver
There's limited information available regarding the impact of Alveofact 50mg Injection. It is recommended to consult your healthcare provider for personalized advice.
Lungs
Consult your health care provider before taking Alveofact 50mg Injection if you have lung diseases.
Driving
Alveofact 50mg Injection does not typically directly affect driving ability. If you experience any side effects, consult your healthcare provider.
Pregnancy
Alveofact 50mg Injection is not directly associated with pregnancy or breastfeeding concerns, as it is primarily used in neonates and infants. However, pregnant individuals should consult healthcare providers before handling or administering surfactant medications due to potential risks associated with exposure to the medication or its residues.
Side Effects of Alveofact 50mg Injection
Alveofact 50mg Injection causes some side effects like all medications, although not everyone will experience them.
Serious:
- Airway blockage
- Infection
- Allergic reactions
- Pulmonary hemorrhage
Common:
- Transient oxygen desaturation
- Changes in heart rate
- Breathing difficulties
Word of Advice
Ensure Alveofact 50mg Injection administration is conducted by trained healthcare professionals familiar with the procedure to minimize the risk of complications. Have proper ventilatory support available before and during administration to manage potential changes in oxygen levels or breathing difficulties. Continuously monitor your vital signs, oxygen levels, and respiratory status during and after administration to promptly address any adverse reactions or complications. Adhere strictly to aseptic techniques during administration to minimize the risk of infection. Ensure proper patient positioning to facilitate the administration process and minimize the risk of aspiration or airway obstruction. Conduct a thorough risk assessment, especially in cases of underlying lung conditions or compromised respiratory function, to determine surfactant therapy's potential benefits and risks.
FAQs about Alveofact 50mg Injection
Q1.
What are the common side effects of Alveofact 50mg Injection?
Common side effects of Alveofact 50mg Injection may include transient oxygen desaturation, changes in heart rate, and temporary breathing difficulties. Serious but rare side effects might include airway blockage, infections, allergic reactions, or pulmonary hemorrhage.
Q2.
Who administers Alveofact 50mg Injection?
Alveofact 50mg Injection is administered by trained healthcare professionals, such as neonatologists, pediatricians, or pulmonologists, with expertise in the procedure and the necessary equipment.
Q3.
Is Alveofact 50mg Injection always successful in improving lung function?
While Alveofact 50mg Injection often improves lung function, individual responses can vary. In some cases, additional support or alternative treatments might be needed.
Q4.
Can Alveofact 50mg Injection be repeated if needed?
Yes, additional doses or repeated administration of Alveofact 50mg Injectionmight be necessary, especially in ongoing respiratory distress or surfactant deficiencies.
Q5.
Does Alveofact 50mg Injection impact long-term lung health?
Evidence suggests that Alveofact 50mg Injection in neonates with RDS can improve short-term outcomes, potentially influencing long-term lung health. However, further research is ongoing to understand its precise long-term effects.
Q6.
How can one know if Alveofact 50mg Injection is effective?
The effectiveness of Alveofact 50mg Injection is assessed based on improved respiratory function, reduced breathing difficulties, and better oxygenation levels observed post-administration. Healthcare providers monitor these parameters closely.
Fact Box of Alveofact 50mg Injection
Molecule name: Alveofact 50mg Injection | Therapeutic class: Pulmonary surfactants |
Pharmacological class: Exogenous pulmonary surfactant | Indications: 1. Neonatal respiratory distress syndrome (RDS) 2. Meconium aspiration syndrome 3. Pneumonia 4. Acute respiratory distress syndrome (ARDS) 5. Lung surfactant deficiency |
References
- Abbvie Ltd, Electronic Medicines Compendium (EMC), [Revised on June 2020] [Accessed on 16th Nov 2023], https://www.medicines.org.uk/emc/files/pil.834.pdf
- Abbvie Ltd, SURVANTA Product monograph, [Revised on 5th Jan 2018] [Accessed on 16th Nov 2023], https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/SURVANTA_PM_EN.pdf
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Dr. Archana Gupta
BDS
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 31 Mar 2026 | 09:31 AM (IST)
Want to know more?
Read Our Editorial Policy
